Aion Therapeutic Inc. (ANTCF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Aion Therapeutic Inc. (ANTCF) trades at $0.00 with AI Score 50/100 (Grade B). Aion Therapeutic Inc. focuses on developing medical cannabis products within Canada. The company rebranded from Osoyoos Cannabis Inc. Market cap: $2.07M, Sector: Healthcare.
Price live · AI analysis from Jun 1, 2026Analyst Coverage for ANTCF: ANTCF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ANTCF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
ANTCF: the 1 perspectives are evenly split.
How is this calculated? →Aion Therapeutic Inc. (ANTCF) Healthcare & Pipeline Overview
Aion Therapeutic Inc. is a Canadian company focused on the medical cannabis sector, offering specialized products within a competitive market. Operating with a negative profit margin and trading on the OTC market, Aion faces challenges in a rapidly evolving industry landscape.
What Is the Investment Thesis for ANTCF?
Investing in Aion Therapeutic Inc. presents significant risks due to its OTC listing and negative profit margin of -1710.9%. The company's gross margin stands at 44.4%. Aion's success hinges on its ability to innovate within the medical cannabis space and effectively market its products in Canada. Potential catalysts include regulatory changes favoring medical cannabis and successful product launches. However, investors should be wary of the risks associated with OTC-listed companies, including limited liquidity and disclosure. The company's beta of -0.55 suggests a negative correlation with the market, but this may not hold true given its small size and specific industry focus. The absence of a dividend further reduces the attractiveness for income-seeking investors.
Based on FMP financials and quantitative analysis
ANTCF Key Highlights
- Market Cap: $0.00B indicates a micro-cap company with limited resources and higher volatility.
- Profit Margin: -1710.9% signals significant losses and potential financial instability.
- Gross Margin: 44.4% suggests the company can generate revenue above the direct cost of goods, but operating expenses are a major concern.
- Beta: -0.55 indicates a negative correlation with the market, but may not be reliable due to the company's size and OTC status.
- Dividend Yield: None reflects the company's current inability to return capital to shareholders.
Who Are ANTCF's Competitors?
ANTCF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ANTCF's Key Strengths?
- Focus on medical cannabis applications.
- Established presence in the Canadian market.
- Potential for product innovation.
- Proprietary cannabis formulations.
What Are ANTCF's Weaknesses?
- Negative profit margin.
- Limited market capitalization.
- OTC listing indicates higher risk.
- Dependence on the Canadian market.
What Could Drive ANTCF Stock Higher?
- Regulatory changes in Canada favoring medical cannabis.
- Successful launch of new cannabis-based products.
- Increasing acceptance of medical cannabis among healthcare professionals.
- Expansion of distribution networks within Canada.
What Are the Key Risks for ANTCF?
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Intense competition from larger cannabis companies.
- Fluctuations in cannabis prices.
- Product recalls or safety concerns.
- Negative profit margin and financial instability.
- OTC listing indicates higher risk and limited liquidity.
What Are the Growth Opportunities for ANTCF?
- Expansion into New Therapeutic Areas: Aion could explore developing cannabis-based treatments for specific medical conditions, such as chronic pain, anxiety, or sleep disorders. The market for cannabis-based pharmaceuticals is growing as research validates its therapeutic potential. Success would depend on clinical trials and regulatory approvals, with a timeline of 3-5 years to commercialization. This could significantly increase their market share within the medical cannabis sector.
- Strategic Partnerships: Collaborating with established pharmaceutical companies or healthcare providers could provide Aion with access to wider distribution networks and expertise in drug development. These partnerships could accelerate product development and market penetration. The timeline for establishing such partnerships is approximately 1-2 years, and the impact could be substantial in terms of market reach and credibility.
- Product Innovation: Developing novel cannabis formulations or delivery methods could differentiate Aion from its competitors. This could include developing new strains with specific cannabinoid profiles or creating innovative products like transdermal patches or inhalers. The timeline for product innovation is approximately 2-3 years, and success would depend on regulatory approval and consumer acceptance.
- Geographic Expansion within Canada: Expanding its distribution network to new provinces and territories within Canada could increase Aion's market reach. This would involve navigating different regulatory frameworks and establishing relationships with local retailers and healthcare providers. The timeline for geographic expansion is approximately 1-2 years, and the impact would depend on the size and potential of the new markets.
- Focus on Medical Cannabis Education: Investing in educational initiatives to inform healthcare professionals and patients about the benefits of medical cannabis could drive demand for Aion's products. This could involve conducting webinars, publishing research, and partnering with medical organizations. The timeline for seeing results from educational initiatives is approximately 2-3 years, and the impact would depend on the reach and effectiveness of the programs.
What Opportunities Does ANTCF Have?
- Expansion into new therapeutic areas.
- Strategic partnerships with established companies.
- Increasing acceptance of medical cannabis.
- Geographic expansion within Canada.
What Threats Does ANTCF Face?
- Intense competition from larger cannabis companies.
- Regulatory changes impacting the cannabis industry.
- Fluctuations in cannabis prices.
- Potential for product recalls or safety concerns.
What Are ANTCF's Competitive Advantages?
- Proprietary cannabis formulations.
- Established relationships with healthcare providers.
- Brand recognition within the Canadian medical cannabis market.
- Intellectual property protection for novel cannabis products.
What Does ANTCF Do?
Aion Therapeutic Inc., formerly known as Osoyoos Cannabis Inc., was incorporated in 2011 and rebranded in August 2020 to reflect its focus on therapeutic applications of cannabis. Headquartered in Toronto, Canada, the company is involved in the development and distribution of medical cannabis products. Aion's products are tailored for the Canadian market, where regulations and consumer demand are evolving. The company aims to leverage cannabis's therapeutic potential, though specific product details and market strategies are not extensively detailed in available information. Aion operates within the broader context of the Canadian cannabis industry, which has seen significant growth and regulatory changes since the legalization of recreational cannabis in 2018. The company's success depends on navigating regulatory hurdles, developing effective products, and establishing a strong market presence. Aion's relatively small market capitalization suggests it is a minor player compared to larger, more established companies in the cannabis sector.
What Products and Services Does ANTCF Offer?
- Develop medical cannabis products.
- Offer cannabis-based therapies for various conditions.
- Engage in research and development of cannabis formulations.
- Distribute medical cannabis products within Canada.
- Focus on therapeutic applications of cannabis.
- Navigate the regulatory landscape of the Canadian cannabis industry.
How Does ANTCF Make Money?
- Develop and market medical cannabis products.
- Generate revenue through product sales.
- Focus on the Canadian medical cannabis market.
- Potentially license intellectual property related to cannabis formulations.
What Industry Does ANTCF Operate In?
Aion Therapeutic Inc. operates in the rapidly evolving Canadian cannabis industry, which has seen significant growth since legalization. The market is characterized by increasing competition and regulatory changes. Companies like Aion face the challenge of differentiating themselves through product innovation and effective marketing. The industry is also subject to evolving consumer preferences and regulatory scrutiny. Aion's ability to navigate these challenges and capitalize on the growing demand for medical cannabis will determine its long-term success. The Canadian cannabis market is projected to continue growing, driven by increasing acceptance and expanding applications of cannabis products.
Who Are ANTCF's Key Customers?
- Patients seeking medical cannabis treatments.
- Healthcare providers recommending cannabis therapies.
- Pharmacies and dispensaries distributing cannabis products.
- Research institutions studying cannabis applications.
F-Score 3/9Financial Health
Aion Therapeutic Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
ROE 191%Key Financial Metrics
Return on equity for Aion Therapeutic Inc. stands at 190.6%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -34.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.12 means current liabilities exceed short-term assets, a liquidity point worth watching.
Aion Therapeutic Inc. (ANTCF) Valuation Context
Valued at $2.07M, ANTCF is classified as a micro-cap stock. Relative to its peer group, ANTCF's quantitative score of 50/100 is below the peer average of 66/100.
ANTCF Revenue & Earnings Trend
In Q1 2025, ANTCF generated $545K in top-line revenue, marking a sequential increase of 56.8%. The company recorded a net loss of $292K, with diluted EPS of $-0.00. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, ANTCF averaged $-0.00 in diluted EPS.
Company Profile
Aion Therapeutic Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Vancouver, CA. The company is led by CEO John Graham Simmonds Jr.. ANTCF has traded publicly since 2021.
ANTCF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Aion's recent insider buying suggests strong confidence from within, mirroring situations like company executives loading up on shares before a major product announcement. The community buzz seems optimistic about Aion's potential in cannabinoid-based therapeutics, seeing parallels to the early days of cannabis stocks. There's a growing perception that Aion is undervalued, reminiscent of how some viewed Tesla before its 2020 surge. The focus on alternative therapies aligns with current market trends, similar to the increasing interest in renewable energy companies.
Bear Case
- Limited information available on Aion's actual revenue streams raises concerns, similar to the dot-com bubble where hype outweighed substance. The community skepticism around the long-term viability of cannabinoid therapeutics is palpable, echoing doubts surrounding novel technologies. Market perception of Aion as a risky micro-cap stock could hinder growth, like the volatility seen in meme stocks. Regulatory hurdles in the pharmaceutical industry could delay product approvals, similar to the challenges faced by biotech startups.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2025 | $544,985 | -$292,464 | -$0.0006 |
| Q4 2024 | $347,625 | -$582,813 | -$0.0012 |
| Q3 2024 | $434,860 | -$370,811 | -$0.0010 |
| Q2 2024 | $145,436 | -$5M | -$0.01 |
Based on FMP financials and quantitative analysis
ANTCF Latest News
No recent news available for ANTCF.
ANTCF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ANTCF.
Price Targets
Wall Street price target analysis for ANTCF.
ANTCF MoonshotScore
What does this score mean?
The MoonshotScore rates ANTCF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: John Graham Simmonds Jr.
CEO
Information on John Graham Simmonds Jr.'s background is not available in the provided context. Without further information, it is impossible to provide details on his career history, education, or previous roles. His experience and qualifications are therefore unknown based on the provided data.
Track Record: Due to the lack of information on John Graham Simmonds Jr.'s background, it is impossible to assess his track record or provide details on key achievements, strategic decisions, or company milestones under his leadership. His contributions to Aion Therapeutic Inc. cannot be evaluated based on the provided data.
ANTCF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Aion Therapeutic Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited operating history, minimal assets, and may be subject to greater regulatory scrutiny. Investing in OTC Other companies carries significant risks due to the potential for fraud, manipulation, and lack of transparency. These companies are not required to adhere to the same stringent reporting standards as those listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity due to low trading volume.
- Lack of transparency due to minimal disclosure requirements.
- Potential for fraud or manipulation.
- Higher volatility compared to exchange-listed stocks.
- Shell Risk Detected indicates a high risk of the company being a shell corporation.
- Verify the company's registration and legal status.
- Investigate the background and experience of the management team.
- Review any available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the company's cash flow and financial stability.
- Understand the risks associated with the OTC market.
- Consult with a financial advisor before investing.
- Company has been incorporated since 2011.
- Focus on the medical cannabis sector.
- Operates in the regulated Canadian market.
- Gross Margin above 0%.
Common Questions About ANTCF (Healthcare)
What does Aion Therapeutic Inc. do?
Aion Therapeutic Inc. is a Canadian company focused on the medical cannabis sector. They develop and distribute medical cannabis products within Canada, targeting patients and healthcare providers. The company aims to leverage the therapeutic potential of cannabis by offering specialized formulations and therapies. Aion operates in a regulated environment and faces competition from other cannabis companies. Their success depends on product innovation, effective marketing, and navigating the evolving regulatory landscape.
What do analysts say about ANTCF stock?
There is no available analyst coverage for ANTCF stock due to its OTC listing and small market capitalization. Therefore, no analyst consensus, valuation metrics, or growth considerations are available. Investors should conduct their own thorough research and due diligence before considering an investment in Aion Therapeutic Inc. The lack of analyst coverage increases the risk and uncertainty associated with this stock.
What are the main risks for ANTCF?
The main risks for Aion Therapeutic Inc. include its negative profit margin, limited market capitalization, and OTC listing. The company faces intense competition from larger cannabis companies and is subject to regulatory changes and fluctuations in cannabis prices. Product recalls or safety concerns could also negatively impact the company's reputation and financial performance. The "Shell Risk Detected" warning further increases the risk associated with this investment. Investors should carefully consider these risks before investing in ANTCF.
What are the key factors to evaluate for ANTCF?
Aion Therapeutic Inc. (ANTCF) holds an AI score of 50/100 (moderate). Not financial advice.
How frequently does ANTCF data refresh on this page?
ANTCF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ANTCF's recent stock price performance?
Aion Therapeutic Inc. (ANTCF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on medical cannabis applications. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ANTCF overvalued or undervalued right now?
Valuing Aion Therapeutic Inc. (ANTCF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ANTCF?
Before investing in Aion Therapeutic Inc. (ANTCF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on Aion Therapeutic Inc.
- OTC stocks are inherently riskier than exchange-listed stocks.
- Financial data may not be up-to-date or reliable.